智通财经APP讯，鲁抗医药(600789.SH)发布公告，公司近日收到中国证券监督管理委员会(简称"中国证 监会")出具的《关于同意山东鲁抗医药股份有限公司向特定对象发行股票注册的批复》(证监许可 [2025]2158号)，同意公司向特定对象发行股票的注册申请。 ...

证券代码:600789 证券简称:鲁抗医药 公告编号:2025-050 山东鲁抗医药股份有限公司 关于向特定对象发行股票申请获得中国证监会同意注册 批复的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送上海证券交易所的申报文件和发行方 案实施。 三、本批复自同意注册之日起12个月内有效。 四、自同意注册之日起至本次发行结束前，你公司如发生重大事项，应及 时报告上海证券交易所并按有关规定处理。 公司董事会将根据上述批复文件和相关法律法规要求以及公司股东大会的 授权，在规定期限内办理本次向特定对象发行股票相关事宜，并及时履行信息 披露义务。敬请广大投资者注意投资风险。 山东鲁抗医药股份有限公司（以下简称"公司"）近日收到中国证券监督 管理委员会（以下简称"中国证监会"）出具的《关于同意山东鲁抗医药股份 有限公司向特定对象发行股票注册的批复》（证监许可[2025]2158号），主要 内容如下： 特此公告。 山东鲁抗医药股份有限公司董事会 2025年9 ...

Core Points - The company has received approval from the China Securities Regulatory Commission for the registration of a stock issuance to specific investors [1] - The approval requires the company to implement the stock issuance plan within 12 months according to the submitted documents to the Shanghai Stock Exchange [1] - The company must report any significant events to the Shanghai Stock Exchange before the completion of the issuance and handle them according to relevant regulations [1] - The company's board of directors will manage the related matters within the stipulated timeframe and fulfill information disclosure obligations [1]

Core Viewpoint - The company is accelerating its global market expansion and promoting the integration of domestic and international trade, driven by the continuous high-level opening-up of the country and the Belt and Road Initiative, aiming to create a new pattern of coordinated development between domestic and international businesses [1] Group 1: Product Development and R&D - The company is focusing on product line construction around "two key areas and six distinctive products," enhancing full-cycle management and implementing a boutique R&D project, achieving phased results in product structure adjustment [1] - The company is strengthening R&D investment, with breakthroughs in innovative drugs and high-end formulations, expecting two innovative drugs to enter Phase II clinical trials and one to enter Phase I clinical trials by mid-2025 [1] Group 2: Sales and Market Strategy - The company adopts a diversified business model primarily based on agency recruitment for domestic formulations, utilizing a comprehensive sales strategy that includes channel distribution, terminal delivery, academic promotion, and more, to cover most market terminals nationwide [2] - By mid-2025, the sales proportion of new products in the company's formulations increased, with new product sales accounting for 31% of the total formulation sales amount [2] - Significant sales growth was observed in products such as Acarbose tablets, Rosuvastatin calcium tablets, and Dapoxetine hydrochloride, with new products accelerating industrialization and forming new revenue growth points [2] Group 3: Internationalization Strategy - The company is advancing its international strategy by enhancing cooperation with global giants and integrating into international supply chains, aiming to expand overseas markets and drive international marketing [3] - The company achieved a breakthrough in international trade revenue, which is expected to exceed 1 billion yuan for the first time in 2024, with continued growth in the first half of 2025 [3] - The export sales of human formulations are projected to approach 100 million yuan in 2024, demonstrating strong market competitiveness [3] Group 4: Registration and Compliance - The company implements a registration-driven export strategy, planning global layouts for all products and enhancing international registration capabilities, achieving 12 new registration certificates and 10 re-registration certificates in 2024 [4] - The company successfully passed international audits for six formulation production lines and received multiple new approvals and re-registration certificates in the first half of 2025 [4] Group 5: Market Expansion and Opportunities - The company is leveraging the opportunities presented by the Belt and Road Initiative to deepen market penetration in emerging markets such as Africa and Central Asia, with increasing sales [5] - The company aims to enhance the synergy between domestic and international markets, seeking new opportunities and promoting high-quality development through dual circulation [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 二、本次收储相关事项的进展情况 2025年9月25日，公司收到第四笔土地补偿款2,000万元。截至目前公司已收到土地补偿款12,227.70万 元，尚未收到补偿款余额23,811.90万元。公司将根据《企业会计准则》等相关规定，对上述补偿款进行 会计处理，具体的会计处理和对相关财务数据的影响以会计师事务所年度审计确认后的结果为准。 三、其他说明 证券代码:600789 证券简称:鲁抗医药 公告编号:2025-049 山东鲁抗医药股份有限公司 关于收到南厂区土地收储补偿款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、情况概述 山东鲁抗医药股份有限公司（以下简称"公司"）分别于2022年8月10日召开第十届董事会第十二次（临 时）会议、2022年9月15日召开2022年第一次临时股东大会，审议通过了《关于政府收储部分国有土地 使用权的议案》，同意公司与济宁市自然资源和规划局签订《济宁市国有建设用地使用权收回合同》， 将公司南厂区五宗国有建设用地237100平方米（ ...

Core Viewpoint - The company has approved the recovery of state-owned land use rights and is in the process of receiving compensation for the land [2] Group 1: Land Recovery Agreement - The company held a board meeting on August 10, 2022, and a shareholder meeting on September 15, 2022, to approve the land recovery agreement with the Jining Natural Resources and Planning Bureau [2] - The company will recover five plots of state-owned construction land totaling 237,100 square meters (approximately 355.65 acres) [2] - The total compensation for the land recovery is set at 360.396 million yuan, which includes a compensation fee of 22.82256 million yuan for land previously owned by Shandong Lukang Pharmaceutical Group [2] Group 2: Compensation Status - The company has completed soil remediation and will transfer the land by June 27, 2024 [2] - As of now, the company has received a total of 122.277 million yuan in compensation, with a remaining balance of 238.119 million yuan yet to be received [2] - The fourth installment of compensation, amounting to 20 million yuan, is expected to be received by September 25, 2025 [2]

2024年9月29日，公司收到第一笔土地收储补偿款2,000万元；2025年5月22 日，公司收到第二笔土地补偿款3,227.70万元；2025年8月27日，公司收到第三 笔土地补偿款5,000万元。具体内容详见公司2024年9月30日、2025年5月23日、 2025年8月28日披露的《关于收到南厂区土地收储补偿款的进展公告》（公告编 号：2024-048、2025-025、2025-042）。 二、本次收储相关事项的进展情况 2025年9月25日，公司收到第四笔土地补偿款2,000万元。截至目前公司已 收到土地补偿款12,227.70万元，尚未收到补偿款余额23,811.90万元。公司将 根据《企业会计准则》等相关规定，对上述补偿款进行会计处理，具体的会计 处理和对相关财务数据的影响以会计师事务所年度审计确认后的结果为准。 证券代码:600789 证券简称:鲁抗医药 公告编号:2025-049 山东鲁抗医药股份有限公司 关于收到南厂区土地收储补偿款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、情况概述 山 ...

Core Viewpoint - The company held a successful half-year performance briefing on September 19, 2025, with full interaction with investors, addressing various inquiries regarding stock issuance, project updates, and financial performance [1][2]. Group 1: Stock Issuance and Financial Performance - The company has submitted a registration application to the China Securities Regulatory Commission for a stock issuance to specific investors, following the Shanghai Stock Exchange's review [1][2]. - The pricing for the stock issuance will be no less than 80% of the average trading price over the 20 trading days prior to the pricing date [1][2]. - The company reported a significant profit decline in the first half of 2025, primarily due to non-recurring gains from asset disposals in the previous year, which amounted to 156 million [2][3]. Group 2: Project Updates - The trans-aconitic acid green bio-manufacturing project commenced production on May 29, 2025, marking a significant step towards industrialization [1]. - The company has over 60 biological pesticide products in production and sales, with three innovative biological pesticides currently under registration [1][2]. - The trans-aconitic acid pesticide formulation is in the testing phase, with plans to submit registration materials in the first quarter of 2026 [1][2]. Group 3: R&D and Product Development - The company has three I-class innovative drugs in clinical trials: TRN-157 for chronic obstructive pulmonary disease in Phase II, CIGB-814 for rheumatoid arthritis in Phase I, and CMS-203, a PDE5 inhibitor for male erectile dysfunction in Phase II [2][3]. - The company is focusing on enhancing operational efficiency and profitability to improve its investment value amidst a competitive pharmaceutical market [2][3].

Policy Developments - The National Healthcare Security Administration (NHSA) released the 11th batch of national drug centralized procurement documents, emphasizing principles of "stabilizing clinical use, ensuring quality, preventing collusion, and countering internal competition" [2] - The new procurement strategy optimizes "anchor prices" by not simply selecting the lowest bid but using the higher value between the average of "comparable unit prices" and the lowest "comparable unit price" at 50% [2] Drug and Device Approvals - Fosun Pharma announced that its subsidiary, Fuhong Hanlin, received EU approval for two drugs, BILDYOS® and BILPREVDA®, for treating osteoporosis in high-risk patients [4] - Renfu Pharma's subsidiary received a tentative FDA approval for Oxcarbazepine extended-release tablets, aimed at treating partial seizures in patients aged 6 and above, with a total R&D investment of approximately 15 million RMB [5] Capital Markets - LuKang Pharmaceutical plans to acquire a 1.9231% stake in Shandong Lukang Hecheng Pharmaceutical Co., with the final amount to be determined through bidding [7] - GE Healthcare responded to rumors about selling its Chinese business, stating its commitment to providing high-quality medical services in China [8] Industry Events - The NHSA announced the interim results of expert reviews for the 2025 National Basic Medical Insurance Directory and commercial insurance innovative drug directory adjustments [10][11] - In the first half of 2025, China's innovative drug licensing transactions reached nearly $66 billion, indicating a significant increase in international recognition and commercial value of Chinese innovative drugs [12] - The National Medical Products Administration established a review center in the Beijing-Tianjin-Hebei region to enhance drug and medical device evaluation services [13] - Approximately 100 rare disease drugs have been included in the basic medical insurance directory, covering 42 types of rare diseases [14]

Core Points - The company held its 11th Board of Directors' 9th (temporary) meeting on September 19, 2025, where several resolutions were passed, including adjustments to the 2025 investment plan and a proposal to acquire shares in Shandong Rukang Hecheng Pharmaceutical Co., Ltd. [1][2][3] Investment Plan Adjustment - The company approved a mid-term adjustment to its 2025 investment plan, increasing the fixed asset investment by 0.08 billion yuan, bringing the total to 5.67 billion yuan, and adding four new long-term equity investment projects with an increase of 1.87 billion yuan [1][6]. Share Acquisition Proposal - The company plans to acquire 1.9231% of the shares in Shandong Rukang Hecheng Pharmaceutical Co., Ltd. through a bidding process managed by the Shandong Property Rights Exchange Center. The final amount will be determined by the bidding results [7][9]. - The acquisition is part of the company's strategic layout and aims to optimize resource allocation and improve operational decision-making efficiency [7][9]. Upcoming Shareholders' Meeting - The company has scheduled its 2025 second temporary shareholders' meeting for October 10, 2025, at 2:00 PM, which will combine on-site and online voting methods [3][22][23].